Carcinoma, Transitional Cell

"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Descriptor ID	D002295
MeSH Number(s)	C04.557.470.200.430
Concept/Terms	Carcinoma, Transitional Cell Carcinoma, Transitional Cell Carcinomas, Transitional Cell Cell Carcinoma, Transitional Cell Carcinomas, Transitional Transitional Cell Carcinoma Transitional Cell Carcinomas

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Carcinoma, Transitional Cell [C04.557.470.200.430]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Transitional Cell".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.

Bar chart showing 21 publications over 12 distinct years, with a maximum of 4 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	0	1	1
2006	1	0	1
2008	1	0	1
2009	2	0	2
2011	1	0	1
2012	1	0	1
2013	1	0	1
2016	3	0	3
2018	2	0	2
2019	4	0	4
2024	3	0	3
2025	1	0	1

Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.

Teplitsky SL, Cranford W, Kim JK, Bell S, Strup S, Allison D, Buchanan A, Myint Z, Strup SE, Martin F, Sood A, Kamat AM, McLouth CJ, Hensley PJ. Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype. Urol Oncol. 2025 Sep; 43(9):521.e19-521.e27.

View in: PubMed
Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, Cirulli GO, Autorino R, Sood A, Rogers C, Abdollah F. Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort. Urol Oncol. 2024 06; 42(6):175.e19-175.e25.

View in: PubMed
Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol ES, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar; 37(3):100424.

View in: PubMed
Cirulli GO, Corsi N, Rakic I, Stephens A, Chiarelli G, Finati M, Davis M, Tinsley S, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis. BJU Int. 2024 05; 133(5):555-563.

View in: PubMed
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.

View in: PubMed
Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, Kamoto S, Tanaka Y, Kato D, Maeda S, Tsuboi M, Chambers J, Uchida K, Nishimura R, Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019; 14(6):e0218382.

View in: PubMed
Holland BC, Sood A, Delfino K, Dynda DI, Ran S, Freed N, Alanee S. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Immunol Immunother. 2019 Jun; 68(6):991-997.

View in: PubMed
Tsuboi M, Sakai K, Maeda S, Chambers JK, Yonezawa T, Matsuki N, Uchida K, Nakayama H. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Vet Pathol. 2019 05; 56(3):369-376.

View in: PubMed
Gild P, Wankowicz SA, Sood A, von Landenberg N, Friedlander DF, Alanee S, Chun FKH, Fisch M, Menon M, Trinh QD, Bellmunt J, Abdollah F. Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urol Oncol. 2018 10; 36(10):469.e1-469.e11.

View in: PubMed
Sood A, Abdollah F, Cole D, Alanee S. Re: Stenting prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268. J Urol. 2018 04; 199(4):1069-1070.

View in: PubMed

People

Explore

Similar Concepts

Top Journals